EA201390740A1 - Способ лечения с использованием ингибитора braf - Google Patents

Способ лечения с использованием ингибитора braf

Info

Publication number
EA201390740A1
EA201390740A1 EA201390740A EA201390740A EA201390740A1 EA 201390740 A1 EA201390740 A1 EA 201390740A1 EA 201390740 A EA201390740 A EA 201390740A EA 201390740 A EA201390740 A EA 201390740A EA 201390740 A1 EA201390740 A1 EA 201390740A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
mutation
braf inhibitor
absence
protein
Prior art date
Application number
EA201390740A
Other languages
English (en)
Inventor
Морин Блим
Тона М. Джилмер
Джеймс Г. мл. Греджер
Сильви Г. Лакерр
Ли Лю
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед filed Critical Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед
Publication of EA201390740A1 publication Critical patent/EA201390740A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Настоящее изобретение относится к способу лечения человека, страдающего меланомой, содержащей мутацию V600, где указанный способ включает детектирование присутствия или отсутствия по меньшей мере одной мутации по меньшей мере в одном белке NRAS, и/или по меньшей мере в одном белке MEK1, или в гене, кодирующем указанные белки, и последующее первичное лечение, изменение лечения или отмену лечения, проводимого с использованием химиотерапевтического средства, выбранного из ингибитора BRaf или другого подходящего агента в зависимости от присутствия или отсутствия указанной мутации.
EA201390740A 2010-11-19 2011-11-18 Способ лечения с использованием ингибитора braf EA201390740A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41562010P 2010-11-19 2010-11-19
US201161559072P 2011-11-12 2011-11-12
PCT/US2011/061408 WO2012068468A1 (en) 2010-11-19 2011-11-18 Method of treatment with braf inhibitor

Publications (1)

Publication Number Publication Date
EA201390740A1 true EA201390740A1 (ru) 2013-12-30

Family

ID=46084426

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390740A EA201390740A1 (ru) 2010-11-19 2011-11-18 Способ лечения с использованием ингибитора braf

Country Status (13)

Country Link
US (1) US20130231347A1 (ru)
EP (1) EP2640387A4 (ru)
JP (1) JP2013543008A (ru)
KR (1) KR20130116291A (ru)
CN (2) CN104689318A (ru)
AU (1) AU2011329666A1 (ru)
BR (1) BR112013012485A2 (ru)
CA (1) CA2818544A1 (ru)
EA (1) EA201390740A1 (ru)
IL (1) IL226352A0 (ru)
MX (1) MX2013005668A (ru)
SG (1) SG190689A1 (ru)
WO (1) WO2012068468A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367970B (es) 2012-08-17 2019-09-11 Hoffmann La Roche Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafinib.
AU2014233805B2 (en) * 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
WO2014193589A1 (en) * 2013-05-29 2014-12-04 Glaxosmithkline Llc Cancer treatment method
DK3019166T3 (da) 2013-07-12 2019-07-29 Piramal Entpr Ltd A Pharmaceutical Combination for the Treatment of Melanoma
WO2015051149A1 (en) * 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof
WO2015059677A1 (en) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
PT3126528T (pt) * 2014-04-04 2021-09-09 Crown Bioscience Inc Taicang Métodos para determinar a responsividade a inibidores de mek/erk
CN106535900A (zh) * 2014-05-06 2017-03-22 加利福尼亚大学董事会 使用braf抑制剂的伤口愈合
CA2953732C (en) 2014-07-14 2023-09-26 Universitat Zurich Prorektorat Mnw Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor
CN104372103B (zh) * 2014-12-05 2017-05-24 武汉友芝友医疗科技股份有限公司 一种nras基因突变检测试剂盒
WO2016116935A1 (en) 2015-01-21 2016-07-28 Yeda Research And Development Co. Ltd. Use of rasa2 as a prognostic and therapeutic marker for melanoma
RU2018105494A (ru) * 2015-07-15 2019-08-15 Селатор Фармасьютикалз, Инк. Улучшенные системы доставки наночастиц
JP2019537604A (ja) * 2016-11-03 2019-12-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｅｇｆｒ／ｐｉ３ｋの小分子二重阻害剤及びその使用
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
CA3214540A1 (en) * 2021-04-22 2022-10-27 Pasi A. Janne Compositions and methods for treating cancer
US20230377140A1 (en) * 2022-02-01 2023-11-23 4D Path Inc. Systems and Methods for Image-Based Disease Characterization
WO2023166345A2 (en) * 2022-03-02 2023-09-07 Novartis Ag Precision therapy for the treatment of cancer
WO2023212071A1 (en) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Combination and the use thereof
WO2023240178A1 (en) * 2022-06-08 2023-12-14 Mapkure, Llc Methods of treating cancer with a b-raf inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2338557T3 (es) * 2003-06-13 2010-05-10 Novartis Ag Derivados de la 2-aminopirimidina utilizados como inhibidores de la raf cinasa.
BRPI0511967B8 (pt) * 2004-06-11 2021-05-25 Japan Tobacco Inc derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende
ES2360608T3 (es) * 2005-08-30 2011-06-07 Novartis Ag Bencimidazoles sustituidos y procedimientos de preparación.
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
EP2056829B9 (en) * 2006-08-16 2012-09-26 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8653045B2 (en) * 2008-02-05 2014-02-18 The Johns Hopkins University Induction of thyroid iodide-handling gene expression in human cancers
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
CA2818544A1 (en) 2012-05-24
EP2640387A4 (en) 2014-08-20
EP2640387A1 (en) 2013-09-25
KR20130116291A (ko) 2013-10-23
WO2012068468A1 (en) 2012-05-24
JP2013543008A (ja) 2013-11-28
MX2013005668A (es) 2013-11-04
IL226352A0 (en) 2013-07-31
SG190689A1 (en) 2013-07-31
CN103402517A (zh) 2013-11-20
AU2011329666A1 (en) 2013-05-30
US20130231347A1 (en) 2013-09-05
CN104689318A (zh) 2015-06-10
BR112013012485A2 (pt) 2016-09-06

Similar Documents

Publication Publication Date Title
EA201390740A1 (ru) Способ лечения с использованием ингибитора braf
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
CY1124951T1 (el) Συνδυαστικη θεραπεια για την αντιμετωπιση των κακοηθειων
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
MX2013000675A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
EA201592304A1 (ru) Способы лечения аутосомно-доминантой гиперхолестеринемии, ассоциированной с мутацией приобретения функции гена pcsk9
IN2012DN01869A (ru)
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2011137320A3 (en) Small molecule inhibitors of usp1 deubiquitinating enzyme activity
MX2013012284A (es) Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
IN2014DN09351A (ru)
EA201490737A1 (ru) Лечение ринита
BR112017024212A2 (pt) sequências de uricases melhoradas e métodos de tratamento
WO2012142300A3 (en) Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event
EA201291206A1 (ru) Мутация в mek1, придающая устойчивость к ингибиторам raf и mek
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
MX2014014097A (es) Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc).
MX340392B (es) Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.